Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB315 Combination Therapy in Advanced Gastric or GEJ Adenocarcinoma
NCT07609667Phase 2Not yet recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of lucansatuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Kelun-Biotech. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
lucansatuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07609667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609667.